tetano
Editor, Senior Moderator
NPJ Vaccines
. 2021 Dec 20;6(1):156.
doi: 10.1038/s41541-021-00419-z.
Preclinical evaluation of a candidate naked plasmid DNA vaccine against SARS-CoV-2
Ria Lassaunière[SUP] #[/SUP][SUP] 1 [/SUP], Charlotta Polacek[SUP] #[/SUP][SUP] 1 [/SUP], Gregers J Gram[SUP] 2 [/SUP], Anders Frische[SUP] 1 [/SUP], Jeanette Linnea Tingstedt[SUP] 1 [/SUP], Maren Krüger[SUP] 3 [/SUP], Brigitte G Dorner[SUP] 3 [/SUP], Anthony Cook[SUP] 4 [/SUP], Renita Brown[SUP] 4 [/SUP], Tatyana Orekov[SUP] 4 [/SUP], Tammy Putmon-Taylor[SUP] 4 [/SUP], Tracey-Ann Campbell[SUP] 4 [/SUP], Jack Greenhouse[SUP] 4 [/SUP], Laurent Pessaint[SUP] 4 [/SUP], Hanne Andersen[SUP] 4 [/SUP], Mark G Lewis[SUP] 4 [/SUP], Anders Fomsgaard[SUP] 5 6 [/SUP]
Affiliations
Abstract
New generation plasmid DNA vaccines may be a safe, fast and simple emergency vaccine platform for preparedness against emerging viral pathogens. Applying platform optimization strategies, we tested the pre-clinical immunogenicity and protective effect of a candidate DNA plasmid vaccine specific for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The DNA vaccine induced spike-specific binding IgG and neutralizing antibodies in mice, rabbits, and rhesus macaques together with robust Th1 dominant cellular responses in small animals. Intradermal and intramuscular needle-free administration of the DNA vaccine yielded comparable immune responses. In a vaccination-challenge study of rhesus macaques, the vaccine demonstrated protection from viral replication in the lungs following intranasal and intratracheal inoculation with SARS-CoV-2. In conclusion, the candidate plasmid DNA vaccine encoding the SARS-CoV-2 spike protein is immunogenic in different models and confers protection against lung infection in nonhuman primates. Further evaluation of this DNA vaccine candidate in clinical trials is warranted.
. 2021 Dec 20;6(1):156.
doi: 10.1038/s41541-021-00419-z.
Preclinical evaluation of a candidate naked plasmid DNA vaccine against SARS-CoV-2
Ria Lassaunière[SUP] #[/SUP][SUP] 1 [/SUP], Charlotta Polacek[SUP] #[/SUP][SUP] 1 [/SUP], Gregers J Gram[SUP] 2 [/SUP], Anders Frische[SUP] 1 [/SUP], Jeanette Linnea Tingstedt[SUP] 1 [/SUP], Maren Krüger[SUP] 3 [/SUP], Brigitte G Dorner[SUP] 3 [/SUP], Anthony Cook[SUP] 4 [/SUP], Renita Brown[SUP] 4 [/SUP], Tatyana Orekov[SUP] 4 [/SUP], Tammy Putmon-Taylor[SUP] 4 [/SUP], Tracey-Ann Campbell[SUP] 4 [/SUP], Jack Greenhouse[SUP] 4 [/SUP], Laurent Pessaint[SUP] 4 [/SUP], Hanne Andersen[SUP] 4 [/SUP], Mark G Lewis[SUP] 4 [/SUP], Anders Fomsgaard[SUP] 5 6 [/SUP]
Affiliations
- PMID: 34930909
- DOI: 10.1038/s41541-021-00419-z
Abstract
New generation plasmid DNA vaccines may be a safe, fast and simple emergency vaccine platform for preparedness against emerging viral pathogens. Applying platform optimization strategies, we tested the pre-clinical immunogenicity and protective effect of a candidate DNA plasmid vaccine specific for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The DNA vaccine induced spike-specific binding IgG and neutralizing antibodies in mice, rabbits, and rhesus macaques together with robust Th1 dominant cellular responses in small animals. Intradermal and intramuscular needle-free administration of the DNA vaccine yielded comparable immune responses. In a vaccination-challenge study of rhesus macaques, the vaccine demonstrated protection from viral replication in the lungs following intranasal and intratracheal inoculation with SARS-CoV-2. In conclusion, the candidate plasmid DNA vaccine encoding the SARS-CoV-2 spike protein is immunogenic in different models and confers protection against lung infection in nonhuman primates. Further evaluation of this DNA vaccine candidate in clinical trials is warranted.